Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Of India Seeks Government Probe Into Trial Manipulator

This article was originally published in PharmAsia News

Executive Summary

India's Glenmark Pharmaceuticals accused a government hospital participating in a trial of one of its drug trials of manipulating data and engaging in unfair practices, causing a halt of the trial. Glenmark filed a complaint with the Drug Controller General of India asking for an immediate audit of the hospital. At issue is Glenmark's Oglemilast asthma drug based on a PDE4 inhibitor molecule. The complaint also questioned whether the screening of volunteers was done properly. (Click here for more

You may also be interested in...



Google Teams Up With Mayo Clinic To Explore AI To Improve Radiotherapy Planning

Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.

FDA’s Final MOU On Interstate Compounding Now Awaits Signatures From States

US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.

Medtronic Expands ENT Portfolio With Ai Biomed Acquisition, NIM Vital Clearance

Ai Biomed’s PTeye helps to identify parathyroid tissue during thyroid surgery. Medtronic ENT also announced the FDA clearance of its NIM Vital electromyographic system for nerve monitoring during surgery.

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel